Manali Kamdar, MD, on Liso-Cel's Continued Efficacy in Second-Line LBCL at 3-Year Follow-up
The associate professor of medicine at University of Colorado discussed updated follow-up data from the phase 3 TRANSFORM trial presented at the 2024 ASCO meeting.
“The FDA approved liso-cel as a second line option for patients with primary refractory and early relapsed large B cell lymphoma if they're transplant eligible based on the TRANSFORM study. So, I think this 3-year update is important to figure out if all of these analyses hold true. The short answer is yes, they do”
Lisocabtagene maraleucel (liso-cel) has continued to demonstrate superiority over standard of care in patients with primary refractory/relapsed (r/r) large B-cell lymphoma (LBCL) with deep responses.1 The therapy was approved under the name Breyanzi for patients with LBCL whose disease was r/r to first-line treatment within 12 months and patients with LBCL whose disease was r/r to first-line treatment who are not eligible for hematopoietic stem cell transplant based off of the primary analysis of the phase 3 TRANSFORM trial (NCT03575351) in 2022.
Updated, 3-year data from TRANSFORM were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 31 to June 4, in Chicago, Illinois, by Manali Kamdar, MD, associate professor of medicine – hematology, University of Colorado School of Medicine - Anschutz Medical Campus, and UCHealth Blood Disorders and Cell Therapies Center. CGTLive® spoke with Kamdar to learn more about the new data and how it continues to support the use of liso-cel for second-line LBCL treatment.
Click here to view more coverage from the 2024 ASCO meeting.
